ORGO Q4 2022 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$116M-10.1% YoY

Gross Profit

$88M76.5% margin

Operating Income

$9M7.5% margin

Net Income

$7M6.5% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

-1.1%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

-$3M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$449M

Total Liabilities

$184M

Stockholders' Equity

$266M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$116M	$129M	-10.1%
Gross Profit	$88M	$96M	-7.9%
Operating Income	$9M	$20M	-57.4%
Net Income	$7M	$52M	-85.5%

Revenue Segments

Advanced Wound care

$109M94%

Surgical and Sports Medicine

$7M6%